BidaskClub lowered shares of Alere Inc. (NYSE:ALR) from a buy rating to a hold rating in a research report released on Sunday morning.

Other research analysts also recently issued reports about the company. Canaccord Genuity reaffirmed a buy rating and set a $51.00 target price on shares of Alere in a research note on Monday, May 22nd. Zacks Investment Research raised Alere from a sell rating to a hold rating in a research note on Tuesday, June 27th. Jefferies Group LLC reaffirmed a hold rating and set a $51.00 target price on shares of Alere in a research note on Thursday, June 1st. BTIG Research reaffirmed a hold rating on shares of Alere in a research note on Wednesday, May 24th. Finally, Craig Hallum downgraded Alere from a buy rating to a hold rating in a research note on Monday, May 15th. Seven analysts have rated the stock with a hold rating, The company currently has a consensus rating of Hold and a consensus target price of $48.00.

Alere (ALR) traded down 0.24% during midday trading on Friday, hitting $50.26. 761,481 shares of the stock traded hands. Alere has a 12 month low of $31.47 and a 12 month high of $50.49. The company’s 50 day moving average price is $49.18 and its 200 day moving average price is $43.12. The firm’s market cap is $4.39 billion.

COPYRIGHT VIOLATION WARNING: “Alere Inc. (NYSE:ALR) Downgraded by BidaskClub to “Hold”” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.watchlistnews.com/alere-inc-nysealr-downgraded-by-bidaskclub-to-hold/1442864.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC increased its position in Alere by 104.6% in the first quarter. Jane Street Group LLC now owns 5,090 shares of the medical research company’s stock valued at $202,000 after buying an additional 115,090 shares in the last quarter. Engineers Gate Manager LP purchased a new position in Alere during the first quarter valued at approximately $265,000. Russell Investments Group Ltd. purchased a new position in Alere during the fourth quarter valued at approximately $312,000. Alambic Investment Management L.P. increased its position in Alere by 48.1% in the first quarter. Alambic Investment Management L.P. now owns 8,000 shares of the medical research company’s stock valued at $318,000 after buying an additional 2,600 shares in the last quarter. Finally, Janus Capital Management LLC increased its position in Alere by 66.7% in the fourth quarter. Janus Capital Management LLC now owns 9,000 shares of the medical research company’s stock valued at $351,000 after buying an additional 3,600 shares in the last quarter. 90.67% of the stock is owned by hedge funds and other institutional investors.

About Alere

Alere Inc is a provider of health information through diagnostic tests. The Company’s segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus.

Analyst Recommendations for Alere (NYSE:ALR)

Receive News & Ratings for Alere Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alere Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.